PFIZER has announced the
voluntary withdrawal of Thelin
(sitaxentan sodium), indicated for
the treatment of pulmonary arterial
hypertension due to liver toxicity,
from the Australian, EU, American
and Canadian markets.
The withdrawal follows a review
of trials and post marketing reports
which found that, the drug can
increase the risk of potentially lifethreatening
idiosyncratic liver injury.
As a result, Pfizer is advising that
no new patients be prescribed
Thelin and that patients currently
using the medication be
transitioned to an alternative
therapy as soon as safely possible.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Dec 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Dec 10
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.